In a move reflecting the changes seen within all major pharmaceutical companies, Merck and Co. recently changed their “Areas of Interest” page on their website to highlight the importance of a robust translational biomarker strategy when looking for an in-licencing deal. The document (http://www.merck.com/licensing/areas_of_interest.pdf) now contains the a footnote at the bottom of pages 14-17 [...] Read more »